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Abstract
Toxaphene is a mixture of chlorinated camphenes and bornanes that was produced and used in the United States until 1982. 1.3 mil-
lion tons of toxaphene have been released worldwide. ‘‘Technical’’ toxaphene (TT) consists of a mixture of up to 800 different chemicals,
known as congeners. TT weathers in the environment by both biotic and abiotic processes. The human body burden of toxaphene con-
sists of only five persistent congeners that are not metabolized; three of these occur in considerably greater amounts than the other two.
Because of the rapid metabolism and excretion of the non-persistent congeners, the persistent congeners that make up the human body
burden most likely play a role in eliciting any potential adverse effects. EPA’s toxicity assessment for TT is based on the occurrence of
liver cancer in rodents, and considerable doubt exists whether this assessment is applicable to weathered toxaphene (WT). Using exper-
imental results from European Union scientists, a reference dose (RfD) was developed for WT based on the three most persistent cong-
eners that comprise the human body burden. The critical effect chosen was tumor promotion and this endpoint is considered protective
for other endpoints as well. Although RfDs are typically derived for non-carcinogenic effects, the endpoint of tumor promotion is appro-
priate for RfD development because the experimental data suggest a dose threshold. The RfD for weathered toxaphene represented by
the sum of the three major persistent congeners (
P
3PC) is 2E05 mg/kg-day. To apply this reference dose to a particular WT mixture,
information is needed regarding the percentage of
P
3PC in the mixture.
Published by Elsevier Inc.
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1. Introduction
Toxaphene is a mixture of chlorinated camphenes and
bornanes that was produced and used in the United States
until 1982. Toxaphene has the distinction of being the most
used pesticide in history with 1.3 million tons having been
released worldwide. Technical toxaphene (TT) consists of a
mixture of up to 800 different chemicals, known as congen-
ers. Once in the environment, TT undergoes weathering by
both biotic and abiotic processes and the number and iden-
tity of the congeners in weathered toxaphene (WT) are dif-
ferent than those in TT. Hence, toxaphene has presented a
significant challenge to analytical chemists (de Geus et al.,
1999, 2000). In addition, WT appears to have toxicity char-
acteristics that are different from TT.
There is a large and growing literature on the analysis,
occurrence, and toxicity of WT (e.g., de Geus et al.,
1999, 2000) Several nomenclature systems have evolved.
Readers unfamiliar with toxaphene chemistry invariably
find multiple names for the same chemical to be a con-
fusing issue. Regarding human exposure to WT, there
are three significant congeners. The structures and names
of these three congeners are shown in Table 1. Enantio-
meric chiral forms exist for many of the congeners. Some
www.elsevier.com/locate/yrtph
Regulatory Toxicology and Pharmacology 44 (2006) 268–281
0273-2300/$ - see front matter Published by Elsevier Inc.
doi:10.1016/j.yrtph.2006.01.001
* Corresponding author.
E-mail address: simonfam@dscga.com (T. Simon).
individual toxaphene congeners are also known as ‘‘Par-
lars’’ after Dr. H. Parlar, a pioneer of toxaphene analyt-
ical chemistry (e.g., Gill et al., 1996). Specific congeners
have been given a Parlar number to easily refer to them
(e.g., Parlar-26 or p-26). The major toxaphene congeners
that persist in fish, marine mammals, human serum, and
human breast milk are p-26, p-50, and p-62 (Table 1).
The congeners p-23, p-40, p-41, and p-44 are also
observed in lower amounts.
Regarding terminology in this paper, TT refers to
the original technical toxaphene mixture; WT refers
to the entire set of congeners remaining after TT
has weathered in the environment; and, as defined in
this paper,
P
3PC refers to the sum of the concentra-
tions of p-26, p-50, and p-62 occurring in either TT
or WT.
1.1. Cancer slope factors for technical toxaphene
In 1991, EPA’s IRIS program developed a cancer slope
factor (CSF) for TT based on two rodent studies, the 1978
Litton Bionetics B6C3F1 mouse study and the 1979 NCI
Osbourne-Mendel rat study that both administered techni-
cal toxaphene via feeding. The slope factor was derived
using the linearized multistage model and had a value of
1.1 per mg/kg-day (e.g., Crump, 1984). In 2000, a peer
review panel reevaluated the CSF for TT and recommend-
ed that the value be reduced to 0.1 per mg/kg-day (Good-
man et al., 2000). The basis of this recommendation was a
reexamination of the original histological materials by an
expert pathology working group and application of
benchmark dose modeling to account for high background
liver tumor rates. In 2003, CAL-EPA (OEHHA, 2003)
Table 1
Nomenclature and structure of the three persistent toxaphene congeners
Parlar name Andrews–Vetter code Wester code IUPAC names of
both chiral forms
Structure
p-26 B8-1413 B[12012]-[202]r 2-endo, 3-exo, 5-endo,
6-exo, 8,8,10,10 octachlorobornane
1
2
3
4
5
6
7
8
9
10
H
Cl
Cl
H Cl
Cl
Cl
H
Cl
Cl
H
H
Cl
CH3
H
or
B[12012]-[202]s 2-exo, 3-endo, 5-exo, 6-endo,
8,8,10,10 octachlorobornane
p-50 B9-1679 B[12012]-[212]r 2-endo, 3-exo, 5-endo, 6-exo,
8,8,9,10,10 nonachlorobornane
1
2
3
4
5
6
7
8
9
10
H
H
Cl H
Cl
Cl
H Cl
Cl
Cl
H
Cl
Cl
H
H
Cl
H
or
B[12012]-[212]s 2-exo, 3-endo, 5-exo, 6-endo,
8,8,9,10,10 nonachlorobornane
p-62 B9-1025 2,2,5,5,8,9,9,10,10 nonachlorobornane
1
2
3
4
5
6
7
8
9
Cl
H
H
Cl
Cl
H
Cl H
Cl
Cl
Cl
Cl
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determined a CSF for TT based on the NCI and Litton
Bionetics rodent studies. The value of the slope factor
was 1.2 per mg/kg-day, essentially the same as the 1991
EPA slope factor. In 2004, Buranatrevedh (2004) derived
a CSF of 0.86 per mg/kg-day from the original rodent data,
also a similar value.
The major and insurmountable difficulty with all of
these derivations is that all are based on application of
TT to rodents and may not be appropriate for evaluating
the potential toxicity of WT to humans.
1.2. Weathering of toxaphene
Toxaphene weathers in different ways in different envi-
ronmental settings to produce different congener mixtures
(Ruppe et al., 2003, 2004). In addition, different animals
metabolize various toxaphene congeners to varying degrees
(Angerhofer et al., 1999) and different species of animals
end up with different toxaphene congener profiles compris-
ing their respective body burdens. Both transformation of
toxaphene mixtures by bacterial action in sediments or
soils and metabolism in animals are considered forms of
‘‘weathering.’’
In animals, including human beings, differences in body
burden are due to differences in the extent that individual
congeners are metabolized and excreted. The major toxa-
phene congeners that persist in fish, marine mammals,
human serum and human breast milk are p-26, p-40/41,
p-44, p-50, and p-62. Barr et al. (2004) reported concen-
trations of toxaphene congeners from pooled human
serum from three US cities. Only p-26 and p-50 were pos-
itively identified in the serum samples. There were indica-
tions that p-40/41, p-44, and p-62 were also present. Gill
et al. (1996) presented methods for toxaphene congener
analysis in serum and observed p-26, p-40/41, p-44, and
p-50 in human serum extracts. Bjerregaard et al. (2001)
measured toxaphene congeners in plasma of Inuit men
and women in Greenland and found detectable levels of
p-26, p-50, and p-62. Polder et al. (2003) measured p-
26, p-50, and p-62 in human breast milk samples from
Kargopol, Severodvinsk, Arkhangelsk, and Naryan-Mar,
Russian towns all north of 60 latitude. Skopp et al.
(2002b) measured p-26, p-41, p-44, and p-50 in human
breast milk obtained from mothers in the north Rhine
area of Germany. Sandanger et al. (2003) measured orga-
nochlorines in the plasma of delivering mothers in north-
ern Russia and found detectable concentrations of p-26
and p-50; p-32, p-38, p-40, p-42, p-44, p-51, p-58, p-62,
and p-69 were not detected. Walker et al. (2003) found
detectable concentrations of p-26 and p-50 in maternal
and umbilical cord blood plasma from mothers and new-
borns in northern Canada; p-32, p-62, and p-69 were ana-
lyzed but not detected. Average percentages of the
congeners in the human body burden were calculated
based on these five sources and are shown in Table 2.
These three congeners, p-26, p-50, and p-62, comprise
about 90% of the average human body burden.
Metabolism and excretion of toxaphene occurs relatively
rapidly in biological systems. These processes are also
considered a form of ‘‘weathering.’’ Oral administration of
toxaphene to mammals and birds results in fecal passage of
about 40% of the administered chemical and metabolism
and urinary excretion of the remaining toxaphene on a
time scale of weeks (Andrews et al., 1996; Biessman et al.,
1983; Pollock and Hillstrand, 1982; Pollock and Kilgore,
1980; Mohammed et al., 1983). Only five or six persistent
congeners remain in the tissues of mammals and birds.
Because of this rapid ‘‘weathering,’’ the exposure of higher
animals to TT or WT is essentially equivalent to
P
3PC
exposure, and any toxic effects are very likely due to
P
3PC.
1.3. Evaluation of risk of tumor promotion using a reference
dose and threshold approach
EPA recently released the cancer guidelines (USEPA,
2005). The greatest emphasis in these guidelines is placed
on understanding the mode of action of potential carcino-
gens and taking the mode of action into account when
developing a toxicity criterion. The guidelines include the
possibility that nonlinear threshold models of cancer will
be considered as the basis of regulatory toxicity criteria.
Ideally, for threshold carcinogens, sufficient data above
and below the dose threshold would exist to perform dose
response modeling (USEPA, 2000); in cases where such
modeling is not feasible, it is appropriate to use the refer-
ence dose approach for evaluation of cancer-associated
chemical such as a tumor promoter that exhibits a dose
threshold.
The reference dose (RfD) derived here is based on a no-
observed-adverse-effect-level (NOAEL) from an in vivo
study in rats administered WT via weekly subcutaneous
injection (Besselink et al., 2000; MATT, 2000). WT was
produced by ‘‘weathering’’ technical toxaphene for 2
months in farmed codfish. Cod liver extract (CLE) was
then used as a source of WT. Concentrations of the three
persistent congeners in CLE were available for all doses
(Besselink et al., 2000; MATT, 2000). The critical effect
was the occurrence of altered hepatic foci (AHF) express-
ing placental glutathione-S-transferase (GSTp-AHF).
These foci are as an indication of tumor promotion (Ito
et al., 1989; Krutovskikh et al., 1991). Additional mecha-
nistic support for endpoint of tumor promotion is provided
by an in vitro study of the disruption of gap junctional
intercellular communication in the Hepa1c1c7 mouse liver
cell line from exposure to WT (Besselink et al., 2000;
MATT, 2000).
Table 2
Toxaphene congeners and their average percentages in the human body
burden from Gill et al. (1996), Polder et al. (2003), Skopp et al. (2002b),
Sandanger et al. (2003), Walker et al. (2003)
Congener p-26 p-40/41 p-44 p-50 p-62
Percent in human body burden 32.8% 2.7% 3.5% 54.7% 6.3%
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Because the RfD derived here is based on the toxicity of
the three persistent congeners, p-26, p-50, and p-62, it is
not directly comparable with other toxicity criteria for
TT and WT. EPA’s cancer slope factor for technical toxa-
phene has different units than the RfD. The tolerable daily
intake (TDI) for WT derived in MATT (2000) is based on
the entire WT mixture and the percentage of
P
3PC may be
different in different WT mixtures.
1.4. Applying the RfD to obtain a cleanup level
If the percentage of
P
3PC in a WT mixture is known,
then cleanup levels may be expressed either in terms ofP
3PC or in terms of WT by back calculation to the appro-
priate WT concentration based on the percentage of
P
3PC
in the mixture. Cleanup levels based the RfD for
P
3PC
may need to be expressed in terms of WT for comparison
with cleanup levels based on other toxaphene toxicity crite-
ria. A numerical comparison and sample calculations are
provided in Section 4. In addition, the analytical methods
used need to be considered; different methods give different
analytical results (de Geus et al., 2000)
2. Derivation of a reference dose for tumor promotion based
on appearance of GSTp-AHF in rat liver
The sole set of toxicity studies that used WT and mea-
sured
P
3PC in the WT mixture was conducted as part
of the European effort, ‘‘Investigation into the Monitoring,
Analysis, and Toxicity of Toxaphene.’’ (MATT, 2000).
These toxicity studies were also published separately (Bes-
selink et al., 2000). Here, we use the results of these toxicity
studies to derive an RfD for
P
3PC.
The standard methods for developing reference doses
have been published elsewhere and are well known (Barnes
and Dourson, 1988). A three-step process for the deriva-
tion of an RfD was followed: (1) choice of a critical effect
for
P
3PC; (2) derivation of NOAELs for
P
3PC from
the in vivo study in the MATT (2000); (3) choice and appli-
cation of appropriate uncertainty factors.
2.1. Critical effect of
P
3PC
Based on the early rodent studies, the critical effect for
TT was liver cancer (e.g., Goodman et al., 2000). Three
possibilities for the critical effect of
P
3PC are considered:
(1)
P
3PC acts as a genotoxic carcinogen; (2)
P
3PC acts as
a developmental toxicant; (3)
P
3PC acts as a carcinogen
via tumor promotion. If
P
3PC acts as a genotoxic carcin-
ogen, then derivation of a cancer slope factor rather than a
reference dose would be appropriate. If
P
3PC acts as
either a developmental toxicant or a tumor promoter and
if these effects have dose thresholds, then derivation of a
reference dose is appropriate.
Recently, EPAhas begun an effort to ‘‘harmonize’’ cancer
and non-cancer risk assessment (USEPA, 1997b, 1998). The
use of an RfD for tumor promotion is consistent with this
‘‘harmonization’’ effort. Colloquia held regarding the frame-
work for human health risk assessment included harmoniza-
tion of cancer and non-cancer endpoints. These colloquia
stressed that understanding the mode of action of a particu-
lar effect was key in understanding toxicity and arriving at a
meaningful regulatory toxicity criterion. The development
of an RfD for the tumor promoting effect of the persistent
congeners of toxaphene that comprise the human body bur-
den is consistent with this effort to harmonize cancer and
noncancer risk assessment, and, as already discussed, also
consistent with EPA’s cancer guidelines (USEPA, 2005).
It is appropriate to consider studies on the toxicity of TT
when considering WT because the ultimate toxicants are
the persistent congeners, present in both TT and WT. In
fact, consideration of the toxicity of TT in a risk assess-
ment for
P
3PC is similar to the practices in EPA’s pesti-
cide program. In that program, because many pesticides
produce their effects through metabolites, the pesticides
can be administered in animal studies to ascertain the toxic
effect of the metabolites, so called ‘‘auto-testing.’’
What follows is a discussion of the likelihood and possi-
ble thresholds of these three possible effects of WT and the
rationale for choosing tumor promotion as the critical
effect.
2.1.1. Genotoxicity of TT or WT
In some studies with prokaryotic systems, TT has been
shown to be mutagenic in the Ames test and others. Both
TT and WT have been shown to be mutagenic in the Ames
test (Young and Freeman, 2001, 2004), but the mutagenic-
ity of WT appears less than that of TT (Steinberg et al.,
1998). Bartos et al. (2005) showed both TT and WT to
be genotoxic in some bacterial systems, but activation of
TT by human microsomal preparations produced a nega-
tive result in the Ames test with salmonella TA 98 and
TA 100, which contain the pKm101 plasmid. In other
work, activation of TT by rat S9 liver fraction produced
a positive Ames test in these strains (Hooper et al., 1979;
Mortelsman et al., 1986).
In eukaryotic systems, the picture is even less clear.
Mutagenicity of TT could not be shown in the mouse dom-
inant lethal assay (NTP, 1979). In studies of sister chroma-
tid exchange in Chinese hamster lung cells and human
lymphocyte cultures, TT produced a weak response that
was reduced by metabolic activation (Sobti et al., 1983; Ste-
inel et al., 1990). Toxaphene was clearly not a mutagen in
the mouse dominant lethal assay (Epstein et al., 1972).
Boon et al. (1998) observed genotoxicity for TT as well
as four toxaphene congeners (p-26, p-32, p-50, and p-62)
in the Mutatox assay. Addition of rat S9 fraction or micro-
somes of harbour seal or albatross decreased the genotoxic
potential of single congeners and TT. This indicates that
organisms with a lower capacity to metabolize toxaphene
might be more susceptible to the mutagenic effects of TT
than organisms with a greater metabolic capacity.
In humans, EPA did not observe leukocyte chromosom-
al aberrations in agricultural workers using toxaphene
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(USEPA, 1978). However, an accidental exposure of eight
women to airborne toxaphene resulted in an increase in
chromosomal aberrations (Samosh, 1974).
There is certainly no clear and convincing evidence that
TT or WT are genotoxic in humans and the critical effect of
cancer via a genotoxic mechanism was not considered
further.
2.1.2. Developmental effects of toxaphene
Calciu et al. (1997) investigated the effects of TT, p-26,
p-50 and an equimolar mixture of p-26/p-50 on the devel-
opment of cultured rat embryos. The concentrations used
were 100, 1000 and 5000 ng/ml. All treatments caused
growth retardation of the embryos at all doses. These
authors suggest that levels of toxaphene in umbilical cord
blood estimated from measured levels in breast milk of
Inuit women are 1/1000 of the lowest concentrations used
in the experiment.
Calciu et al. (2002) discovered an interaction between
TT, p-26, and p-50, on one hand, and hyperglycemia, on
the other hand, that affected the development of cultured
rat embryos. The dose range was 100, 1000, and 5000 ng/
ml. Again, the levels of toxaphene or individual congeners
used appear to be at least 1000 times greater than the levels
of toxaphene predicted in cord blood based on plasma lev-
els in Inuit women (Bjerregaard et al., 2001) and Calciu
et al. (2002) concluded that observing effects in humans
would be unlikely. Thus, while both TT and WT may pro-
duce developmental toxicity, it appears that the concentra-
tions required to do so are much higher than body burden
concentrations in a highly exposed human population.
Because TT and the two congeners were added directly
to the culture medium containing the rat embryos, it is
impossible from this in vitro experiment to determine an
estimate of the dose that would be associated with human
developmental effects. Nonetheless, a LOEC (Lowest
Observed Effective Concentration) of 100 ng/ml or
100 lg/L can be established for TT, p-26, and p-50 from
this study.
2.1.3. Toxaphene as a tumor promoter
Inhibition of gap junctional intercellular communication
(GJIC) has been postulated to release initiated cells from
suppressing effects of signals passing from surrounding
cells (Kao et al., 1995; Yamasaki, 1990). Disruption of
gap junctional communication can be measured by
intercellular transfer of the dye Lucifer yellow following
application of the tumor promoter 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) (McKarns and Doolittle,
1982). A study by Kang et al. (1996) showed that noncyto-
toxic concentrations of TT inhibited GJIC in normal
human breast epithelial cells in a dose-dependent way after
90 min of exposure.
The appearance of GSTp-AHF is associated with a
decrease in GJIC with surrounding cells and eventual pro-
gress to cancer (Ito et al., 1989; Krutovskikh et al., 1991).
This effect appears to be due to reduced expression of con-
nexins, the gap junction forming protein (Fitzgerald et al.,
1989). However, the association is not complete and dis-
ruption of gap junctions and down-regulation of connex-
ins, on one hand, and the expression of GSTp, on the
other hand, may represent two distinct pathways to tumor
formation (Bager et al., 1997). Toxaphene and other non-
genotoxic carcinogens have been shown to disrupt GJIC
(Kang et al., 1996; Kolaja et al., 2000).
Based on these earlier studies, Besselink et al. (2000)
investigated the tumor promoting effects of WT using both
in vivo and in vitro assays. The cod liver extract used in the
MATT study clearly disrupted gap junctions in mouse
Hepa1c1c7 cells at all concentrations tested (Besselink
et al., 2000) and tumor promotion is considered the most
likely endpoint for WT.
2.2. Description of the study providing the critical effect
2.2.1. Preparation of weathered toxaphene mixture
Weathered toxaphene was prepared by dosing codfish
with 30 ppm TT via feed pellets for two months. Cod liver
extracts (CLE) were used as the source of weathered toxa-
phene. At the conclusion of the feeding period, a total of
1880 mg of toxaphene residue was obtained from the
pooled cod livers (MATT, 2000). Analysis of the CLE
revealed a mixture of many toxaphene congeners, including
p-26, p-50, and p-62. As indicated, because of rapid metab-
olism and excretion of the non-persistent congeners, expo-
sure of mammals to technical toxaphene or WT mixtures is
essentially equivalent to exposure to
P
3PC, and any toxic
effects are likely due to
P
3PC.
A chromatogram provided in the MATT report shows
that the CLE was considerably enriched in p-26, p-32, p-
50, and p-62. However, the mixture of toxaphene residues
in CLE was complex and contained more individual cong-
eners than weathered toxaphene obtained from other biotic
sources (Chan et al., 1998; Chan and Yeboah, 2000; Skopp
et al., 2002a; Maruya, 2000). Technical toxaphene was
weathered in cod for two months only to produce CLE.
The percentage of
P
3PC in CLE was between 0.2 and
0.3%, which was much lower than the percentage observed
in WT from environmental sources (e.g., Tables 6 and 7)
The low percentage of
P
3PC in CLE may be related to
the short period of weathering.
2.2.2. In vivo study of tumor promotion
Female Sprague–Dawley rats in groups of three or four
animals were given partial hepatectomies at the age of 6
weeks. Diethylnitrosamine (30 mg/kg) was given by intra-
peritoneal injection 24 h after hepatectomy. Beginning 5
weeks later and lasting for 20 weeks, the rats were then
dosed weekly via subcutaneous injection with either
technical toxaphene (TT), UV-treated toxaphene (UVT),
cod liver extract (CLE) or dioxin (2,3.7.8-TCDD) in a
corn oil vehicle. The lowest concentration of CLE in the
in vivo study was 0.46 mg/ml corn oil and the highest
concentration was 12.5 mg/ml corn oil. 1 ml of corn oil
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was administered subcutaneously per week. MATT (2000)
indicates these dosing concentrations are expressed as
UVT-equivalents whereas Besselink et al. (2000) report
these numeric values only.
Presumably, because UV treatment is another means of
weathering toxaphene, the doses in CLE were expressed as
UVT equivalents, although both MATT (2000) and Besse-
link et al. (2000) failed to provide the details of this equiv-
alence or the rationale for the UV treatment. Here, the
concentrations of
P
3PC were used as the basis of the
RfD dose because these are the predominant congeners
in the human body burden. Concentrations of p-26, p-50,
and p-62 in CLE were provided in MATT (2000) and the
details of the UVT equivalence are not necessary.
A range of doses of TT, UVT, and CLE were given to
the rats. A single dose of dioxin was given as a positive con-
trol. One week after the last dose, the rats were sacrificed
and their livers obtained (Besselink et al., 2000; MATT,
2000).
The endpoint of the in vivo assay was the production of
GSTp-AHF. Only TCDD produced positive foci. The low-
er three doses of CLE were not significantly different from
the corn oil control in terms of the number of GSTp-AHF.
The highest dose showed a decrease in GSTp-AHF, indi-
cating some possible cytotoxic effect that may not be relat-
ed to tumor promotion.
The ratios of the three persistent congeners in the doses
used in the in vivo assay approximate those observed in
biotic samples (Table 5). Hence,
P
3PC is approximately
proportional to the dose of WT. The concentrations of
the three persistent congeners in the rats’ livers were mea-
sured at the end of the experiment. Only the highest dose
(12.5 mg/kg-week) resulted in detectable liver concentra-
tions with detections of 2 and 3 lg/kg wet weight for
p-50 and p-62, respectively, and a nondetect analytical
result for p-26 (Table 3).
Because of the difficulty of interpreting the in vivo
results observed at the highest dose of CLE (12.5 mg/kg-
week), the next highest dose was considered a NOAEL.
At this next highest dose of 4.17 mg/kg-week as UVT
equivalents, the number of GSTp-AHF was not significant-
ly different from the number of GSTp-AHF in corn oil con-
trols. This dose is equivalent to 0.0021 mg/kg-day ofP
3PC (Table 2). However, with this dose of 4.17 mg/kg-
week CLE as UVT equivalents, concentrations of p-26,
p-50, and p-62 in the rats’ livers were below analytical
detection limits (Table 3).
2.2.3. In vitro study of gap junctional intercellular
communication
The in vitro study measured intracellular communica-
tion between mouse Hep1c1c7 cells in culture by observing
the spread of Lucifer Yellow dye between adjacent cells.
This dye has been used for a number of years to observe
disruption of gap junctional communication and electrical
junctions between nerve cells. (e.g., McKarns and Doolit-
tle, 1982; Spencer and Satterlie, 1980). 2,3,7,8-TCDD was
used as a positive control. A dose-dependent response
was observed for CLE in this assay. The lowest concentra-
tion for CLE extract in the in vitro study was 1 mg/ml (Bes-
selink et al., 2000). In the in vitro study, an effect was
observed at 1 mg/ml—hence, this concentration represents
Table 3
Percentage of p-26, p-50, and p-62 in the MATT dosing vehicle and calculated doses of
P
3PC in the in vivo study
Concentration UV-T equivalents (mg/ml oil) 0.46 1.39 4.17 12.5
Concentration (lg/ml oil)
p-26 0.3 1.2 3.4 9.9
p-50 0.4 2 5.5 16.8
p-62 0.4 2.1 6 17.5
P
3PC 1.1 5.3 14.9 44.1
Percentages of three congeners in CLE
%p-26 0.065 0.086 0.082 0.079
%p-50 0.087 0.144 0.132 0.134
%p-62 0.087 0.151 0.144 0.140P
3PC 0.239 0.381 0.357 0.354
Doses (mg/kg-day) used in the in vivo study
CLE as UVT 0.066 0.198 0.60 1.79
p-26 4.28E05 0.00017 0.00049 0.0014
p-50 5.71E05 0.00029 0.00079 0.0024
p-62 5.71E05 0.00030 0.00086 0.0025P
3PC 1.57E04 0.00076 0.0021 0.0063
Liver concentrations in the in vivo study (lg/kg)
p-26 <0.4 <0.4 <0.5 <1.0
p-50 <0.5 <0.4 <0.5 2
p-62 <0.5 <0.5 <0.5 3
P
3PC <1.4 <1.3 <1.5 5–6
The chosen NOAEL is in boldface and highlighted.
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a LOEC for CLE. The corresponding LOEC for
P
3PC
based on a concentration of CLE of 1 mg/ml would be
2.4 lg/ml because the percentage of
P
3PC in CLE at the
lowest dosing concentration is 0.24% (Table 3).
Kang et al. (1996) used technical toxaphene in an in vitro
assay of GJIC in normal human breast epithelial cells and
observed a LOEC of 1.25 mg/ml. This result is not directly
comparable to those from MATT (2000) because of three
factors: (1) the differences between WT and TT; (2) the fact
that the percentage of
P
3PC in TT used by Kang et al.
(1996) is not known; and (3) an internal discrepancy in
Kang et al. (1996) whether toxaphene concentrations were
expressed in mg/ml or lg/ml.
2.3. Determination of a NOAEL for tumor promotion from
the MATT study
Generally, it is preferable to develop a point of depar-
ture for an adverse effect using benchmark dose modeling
(USEPA, 2000). These models use all the data from dose
response studies instead of a NOAEL or LOAEL. Howev-
er, in the in vivo study (Besselink et al., 2000; MATT,
2000), the doses were not high enough to observe a dose–
response curve or even a LOAEL.
The doses of
P
3PC were recalculated based on the rats’
initial average body weights and average weight gains given
in Table 4 of chapter 5 of the MATT report. These doses
are also shown in Table 3 of this paper.
As indicated, at the highest in vivo dose of 12.5 mg/kg-
week CLE, there was a reduction in the number of GSTp-
AHF in the rats’ livers compared with the number in con-
trols and the highest dose group result was not considered
usable. No differences were observed in the number or size
of GSTp-AHF foci at the three lower doses. The highest
dose of these three (4.17 mg/kg-week CLE as UVT equiv-
alents) was below the dose threshold for observing the crit-
ical effect. Hence, this dose of 4.17 mg/kg-week CLE or
0.002 mg/kg-day of
P
3PC can be considered a NOAEL
(Table 3).
The rats’ liver concentrations of p-26, p-50, and p-62
were measured at the conclusion of the study. This infor-
mation was presented in MATT (2000) but not in Besselink
et al. (2000). At the highest dose of 12.5 mg/kg-week of
CLE, the concentration in the rats’ livers of
P
3PC was less
than 6 lg/kg wet weight (Table 3 in chapter 5 of MATT
(2000) and Table 3 here). At lower doses, the concentra-
tions of the three persistent congeners were below analyti-
cal detection limits.
To compare the internal liver concentration of
P
3PC in
the in vivo study with the LOEC from the in vitro study,
one can multiply the percentage of
P
3PC and the CLE
concentration. The in vitro LOEC for CLE was 1 mg/ml
(Besselink et al., 2000). The percentage of
P
3PC in CLE
at this lowest dose level was 0.24%. Hence, assuming the
intact rat liver cells are similarly susceptible to interruption
of GJIC as the Hep1c1c7 cells, the potentially effective con-
centration of
P
3PC in the rats’ livers would be 0.24% of
the in vitro LOEC of 1 mg/ml or 2.4 lg/ml of
P
3PC.
Expressing this value in the same units as
P
3PC in the
rats’ livers (Table 2), it becomes 2400 lg/L (assuming
1 kg of tissue occupies 1000 ml). Hence, this LOEC is 400
times larger than the largest liver concentration observed,
approximately 6 lg/kg of
P
3PC.
The NOAEL for
P
3PC based on the dose given the rats
in the in vivo study and the percentage in the CLE mixture
is 0.002 mg/kg-day and corresponds to 4.17 mg CLE per
ml of corn oil (Table 3).
2.4. Application of uncertainty factors applied to obtain an
RfD for tumor promotion
The usual uncertainty factors of 10 for animal-to-hu-
man extrapolation and 10 for human variability result
in a combined UF of 100. To support this value, it is
Table 4
Margin of exposure for developmental effects among the Inuit based on developmental effects in cultured rat embryos
Chemical Daily intake
(lg/kg-day)
Median maternal plasma or cord
blood conc. (lg/L)
Effect level (Calciu et al., 1997, 2002)
(lg/L)
Margin of exposure
Walker et al.
(2003)
Sandanger et al.
(2003)
Walker et al.
(2003)
Sandanger et al.
(2003)
p-26 0.010a 0.02 0.05 100b 5000 2000
p-50 0.016a 0.03 0.09 100 2000 1111
a Intakes for p-26 and p-50 were estimated based on median values of 4% p-26 and 6% p-50 (Table 5) and a WT intake of 0.26 lg/kg-day Skopp et al.
(2002b), Chan and Yeboah (2000), Chan et al. (1997).
b Effect level concentration for TT, p-26 or p-50.
Table 5
Preliminary remediation goals (PRGs) USEPA (2004b) for weathered toxaphene
Medium Residential soil (mg/kg) Industrial soil (mg/kg) Air (lg/m3) Water (lg/L)
Percentage of
P
3PC in WT 10 10 8.8 5P
3PC PRG 1.2 12 0.07 0.03
Corresponding WT PRG 12 120 0.8 0.6
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necessary to consider possible developmental effects and
database insufficiencies, which might add additional uncer-
tainty factors.
2.4.1. Margin of exposure for developmental effects of
toxaphene
The rat embryo studies of Calciu et al. (1997, 2002) pro-
vide a LOEC value of 100 lg/L. One can compare this val-
ue with plasma concentrations in highly exposed humans.
Generally, extrapolation from in vitro effects to potential
in vivo effects is not typically performed. Nonetheless, a
margin-of-exposure (MOE) can be calculated as the ratio
between this LOEC and actual plasma levels in these highly
exposed humans as an estimate of the likelihood of devel-
opmental effects in humans. The larger the value of this
MOE, then the less the need for an additional uncertainty
factor for possible developmental effects.
Both the Inuit, a circumpolar aboriginal population in
Canada and Greenland, and people living in northern Rus-
sia, have high intakes of WT because of their dependence
on fish and marine mammals as a food source (Arbour
et al., 2004; Bjerregaard et al., 2001; Receveur et al.,
1998; Sandanger et al., 2003; Van Oostdam et al., 2005;
Walker et al., 2003). Mean plasma levels in delivering
mothers (Sandanger et al., 2003) and mean umbilical cord
blood levels (Walker et al., 2003) of toxaphene congeners
can be compared to the LOEC for developmental effects
in rat embryos (Calciu et al., 1997, 2002).
Table 4 shows these values and provides a calculation of
the margin of exposure for frank effects based on the rat
embryo data with p-26 and p-50 as the toxicants (Calciu
et al., 1997). The MOEs for both p-26 and p-50 are for
both human studies greater than 1000. It is also notewor-
thy that the rats administered the NOAEL value of CLE
failed to accumulate any measurable amount of any toxa-
phene congeners in their livers (Besselink et al., 2000;
MATT, 2000). hence, a much higher external dose than
the NOAEL would be needed to produce an internal con-
centration similar to that of 100 lg/L used by Calciu et al.
(1997).
There is no evidence that the Inuit experience greater
developmental health effects due to toxaphene exposure
than do developed societies (Faustman et al., 2000; Landr-
igan et al., 2002). Birth defects among the Inuit have been
attributed to other causes such as nutrition and alcoholism
and increasing ‘‘Westernization’’ of their culture (Arbour
et al., 2004; Macaulay et al., 2004). Hence, it is likely that
the level of human intake that results in the measured plas-
ma and cord blood levels shown in Table 4 is well below the
threshold for developmental effects.
2.4.2. Estimate of a NOAEL based on human intakes of
toxaphene congeners
Estimates of daily WT intakes from fish and biota
among the Inuit (Chan et al., 1997) can be used to estimate
daily intake and compare this to the NOAEL in rats based
on GSTp-AHF. The 95th percentile estimated intake for
Inuit females is 2.6 lg/kg-day. Using the average percent-
age value of
P
3PC in fish of 22.5% (Table 6), the 95th per-
centile
P
3PC intake would be 0.0006 mg/kg-day, about
one-third of the NOAEL value of 0.002 mg/kg-day. Hence,
it is very likely that an RfD derived from the rat NOAEL
will be protective of developmental effects in humans.
2.4.3. Other potential toxic effects of toxaphene
Other endpoints were considered, although in less detail
than those discussed above. These other endpoints were
studied using TT, (Andrews et al., 1996; Biessman et al.,
1983; Pollock and Hillstrand, 1982; Pollock and Kilgore,
1980; Mohammed et al., 1983). Because of the rapid metab-
olism and excretion of TT in higher animals and the con-
cept of ’’auto-testing’’ as previously discussed, TT studies
are appropriate for contributing to the breadth of end-
points considered for
P
3PC and contribute to the strength
of the database regarding potential effects of
P
3PC. How-
ever, these other studies are not directly comparable to the
NOAEL for
P
3PC because the concentration of
P
3PC in
these studies was not known. However, these studies can be
compared to the NOAEL expressed as the dose of CLE,
which is 0.6 mg/kg-day (Table 3).
Both Arnold et al. (2001) and Bryce et al. (2001)
observed a decrease in serum cholesterol in Cynomolgus
monkeys in monkeys given doses of 0.8 mg/kg-day and
1 mg/kg-day respectively. Tryphonas et al. (2000, 2001)
observed immunologic effects in Cynomologous monkeys
dosed with TT. The NOAEL for these effects is 0.1 mg/
kg-day. Olson et al. (1980) observed neurodevelopmental
effects in rats for TT with a LOAEL of 0.5 mg/kg-day.
Chu et al. (1988) observed liver effects in rats with a
NOAEL of 0.35 mg/kg-day and thyroid effects with a
NOAEL of 0.18 mg/kg-day. All of these point-of-depar-
ture values are similar to the NOAEL of 0.6 mg/kg-day
for the CLE mixture and an uncertainty factor for database
insufficiency is not necessary.
2.4.4. Toxaphene congeners and human cancer
With regard to breast cancer specifically, TT, p-26, and
p-50 all enhance proliferation of MCF7-E3 human breast
cancer estrogen-sensitive cells in vitro (Stelzer and Chan,
1999). In this same cell line, TT, p-26, and p-60 have weak
anti-estrogenic properties and can potentially disturb the
intracellular signaling mediated by the estrogen receptor
(Arcaro et al., 2000; Bonefield et al., 1997) and a link has
been suggested between toxaphene and breast cancer. In
addition, toxaphene disrupts GJIC and expression of gap
junction proteins in normal human breast epithelial cells
(Kang et al., 1996). However, the highly expose Inuit have
been shown to have very low breast cancer rates, about 1/
10 of the average rate in Canada (Gaudette et al., 1996;
Miller and Gaudette, 1996).
With regard to cancer, there is also currently no defini-
tive evidence that the circumpolar Inuit experience greater
cancer risk due to toxaphene exposure than developed
societies. The Inuit present a dissimilar picture when one
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considers the relative frequencies of various types of
cancers within the population; however, the etiology
remains unclear (Gaudette et al., 1993; Nielsen et al., 1996).
For the reasons of the high MOE for developmental
effects, the NOAEL based on human intake estimates,
the plethora of TT studies on a variety of endpoints
and the lack of concordance of laboratory and human
population effects of toxaphene regarding cancer, an addi-
tional UF for developmental effects or database insuffi-
ciency will not be included and the combined UF is 100.
Hence, the RfD for
P
3PC is 2E05 mg/kg-day.
3. Estimating the risk consuming fish containing weathered
toxaphene
From the MATT (2000), the percentages of the three
persistent congeners in the corn oil used as a dosing vehicle
in the in vitro or in vivo studies (Table 2) are compared
with the median values from the fish and shellfish concen-
trations obtained from sources at northern latitudes (Table
6) or from a Superfund site (Table 7). Note that the per-
centages of the three congeners are lower in the MATT
dosing vehicle than in fish or biota from the environment.
The reason for the lower percentage of
P
3PC in CLE may
be that TT was weathered in codfish for only two months;
over time, toxaphene residues in biota will become enriched
in the persistent congeners and the fish and biota data in
Tables 6 and 7 were obtained from tissue in which TT
had been weathered for years.
As an example of a risk calculation with the
P
3PC RfD
derived here, data from fish and shellfish obtained from a
Superfund site in the southeastern US were obtained from
Maruya (2000). Ninety-five percent upper confidence limits
on the arithmetic mean concentrations of WT and
P
3PC
concentrations in the fish were calculated with PROUCL
software (USEPA, 2004a). Finfish and shellfish concentra-
tions in ng/g wet weight were both included in the calcula-
tion. No weighting was used for angler preference of the
two types of fish. WT concentrations were generally consis-
tent with a lognormal distribution. Because several nonde-
tect analytical results were present, the bootstrap-t method
was used for the UCL. TheUCLvalue forWTwas 5348 lg/
kg.
P
3PC concentrations were consistent with a gamma
distribution and the adjusted gamma method was used for
the UCL. The UCL value for
P
3PC was 228 lg/kg.
Fish ingestion rates for both children and adults were
obtained from Tables 10–61 of the Exposure Factors
Handbook (USEPA, 1997a). The highest value of
Table 6
Percentages of three congeners in total toxaphene concentrations in various biotic samples (based on ng/g wet weight)
Source %p-26 %p-50 %p-62 %
P
3PC Reference
King Salmon 4.12 5.76 9.41 19.29 Chan and Yeboah (2000)
Dogfish 4.09 5.16 9.14 18.39 Chan and Yeboah (2000)
King Salmon 4.11 6.56 7.67 18.33 Chan and Yeboah (2000)
King Salmon 3.70 6.30 7.26 17.26 Chan and Yeboah (2000)
King Salmon 4.59 6.89 10.00 21.49 Chan and Yeboah (2000)
Whitefish 3.50 6.50 9.75 19.75 Chan and Yeboah (2000)
King Salmon 4.00 5.00 7.67 16.67 Chan and Yeboah (2000)
King Salmon 3.66 5.00 7.93 16.59 Chan and Yeboah (2000)
Trout 3.96 3.96 6.04 13.96 Chan and Yeboah (2000)
King Salmon 3.08 5.94 6.78 15.80 Chan and Yeboah (2000)
King Salmon 5.00 7.42 7.26 19.68 Chan and Yeboah (2000)
Halibut 7.86 9.29 6.19 23.33 Chan and Yeboah (2000)
Ooligan 2.26 2.71 4.71 9.68 Chan and Yeboah (2000)
Chum Salmon 2.84 4.33 6.72 13.88 Chan and Yeboah (2000)
Trout 5.02 6.39 13.24 24.66 Chan and Yeboah (2000)
Trout 4.12 7.41 10.70 22.22 Chan and Yeboah (2000)
Trout 4.42 7.28 13.11 24.81 Chan and Yeboah (2000)
Sockeye 2.29 1.98 3.75 8.02 Chan and Yeboah (2000)
Lake Trout 6.36 5.45 11.82 23.64 Chan and Yeboah (2000)
SRM 1588 cod liver oil 6.38 9.83 4.84 21.06 Chan and Yeboah (2000)
Burbot 2.79 4.12 1.76 8.68 Skopp et al. (2002a,b)
Burbot 6.88 5.74 2.10 14.72 Skopp et al. (2002a,b)
Muskox 0.33 0.45 Skopp et al. (2002a,b)
Beluga 14.01 25.07 0.80 39.88 Skopp et al. (2002a,b)
Narwhal 16.41 20.00 2.24 38.65 Skopp et al. (2002a,b)
Walrus 12.03 6.86 0.33 19.22 Skopp et al. (2002a,b)
Whitefish 13.48 23.60 40.45 Chan et al. (1998)
Lake Trout 10.37 23.70 40.37 Chan et al. (1998)
Narwhal 29.99 25.40 58.05 Chan et al. (1998)
Minimum 0.33 0.45 0.33 8.02
Maximum 29.99 25.40 13.24 58.05
Median 4.12 6.39 7.26 19.49
Average 6.61 8.76 6.85 22.45
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0.369 g/kg-day for consumption of recreationally caught
fish is representative of children aged six was used here.
Please note that this value will also be protective of adults.
In general, site-specific data on fish consumption is prefer-
able to default values such as these. Hence, it may be advis-
able to obtain site-specific fish consumption data for this
Superfund site in the future. In this study, the risk estimates
for consumption of fish at this Superfund site are based on
these default consumption rates.
HQ ¼ Cfish  IRfish
RfD
; ð1aÞ
where HQ is the hazard quotient, Cfish is the concentration
in fish = 228 lg/kg, IRfish is the ingestion rate of
fish = 0.369 g/kg-day, RfD is the reference do-
se = 2E05 mg/kg-day.
Substituting the values and converting units as follows
yields a hazard quotient value of 4 for
P
3PC.
HQ¼
228
lgR3PC
kgfish
 0:001mgR3PClgR3PC  0:369
gfish
kgBW day
 0:001kgfishgfish 
2E 05 mgR3PC
kgBWday
¼ 4
ð1bÞ
3.1. Application and development of preliminary remediation
goals using the RfD for WT
In applying the RfD for
P
3PC for the development
of preliminary remediation goals (PRGs) (USEPA,
2004b) or cleanup levels, back calculation is needed to
obtain the PRG concentration of WT that corresponds
to
P
3PC based on the percentage of
P
3PC in the
WT mixture. There has been considerable and contin-
uing debate over the appropriate analytical methods
for WT (de Geus et al., 2000). The key message here
is that it will likely be necessary to know the concentra-
tion of
P
3PC for risk assessment and this concentra-
tion needs to be related to the total WT
concentration. This may be possible with a range of
analytical methods, but the risk assessor should remain
cognizant of this possible pitfall of different results with
different analytical methods.
The methodology and exposure assumptions used in
the Region 9 Table of PRGs were used to develop
PRGs for WT based on
P
3PC. For air, the percentage
of
P
3PC in WT was estimated from Bidleman et al.
(2004) at 8.8%. For soil, the percentage of
P
3PC in
WT was assumed to be 10%; for water, 5%. PRGs
for both
P
3PC and WT based on the toxicity ofP
3PC are shown in Table 5. Please note that it is
not appropriate to use these WT PRGs as cleanup lev-
els without site-specific determination of the percentage
of
P
3PC in WT.
4. Discussion
4.1. Is the CLE representative of WT?
It should be clear from the few (2–5) congeners that
comprise the human body burden versus the many congen-
Table 7
Percentages of the three congeners in total toxaphene concentrations in
fish samples from a Superfund site
Source %p-26 %p-50 %p-62 %
P
3PC
Black Drum 2.71 2.71
Blue Crab 6.09 1.50 0.33 7.92
Blue Crab 4.72 2.37 1.09 8.19
Blue Crab 5.39 2.86 8.24
Blue Crab 4.39 4.39
Blue Crab 0.89 0.66 1.56
Blue Crab 2.10 2.15 4.25
Blue Crab 4.45 2.29 0.65 7.39
Blue Crab 4.52 1.20 5.72
Croaker 2.39 0.59 2.98
Croaker 2.32 0.63 2.95
Croaker 2.24 0.41 2.64
Croaker 2.47 0.62 3.10
Mullet 4.19 1.37 0.73 6.29
Mullet 1.94 1.91 0.74 4.59
Mullet 3.62 1.47 0.47 5.55
Mullet 2.59 0.92 3.51
Mullet 3.92 1.23 0.67 5.82
Mullet 0.28 1.43 0.49 2.21
Mullet 3.13 1.50 0.61 5.24
Mullet 4.42 0.69 5.11
Mullet 4.03 1.57 5.60
Red Drum 3.37 1.29 0.64 5.29
Red Drum 2.78 0.88 0.46 4.12
Red Drum 2.85 2.85
Sea Trout 3.92 1.40 0.54 5.86
Sea Trout 0.92 1.05 0.70 2.67
Sea Trout 3.19 0.92 0.53 4.63
Sea Trout 2.54 0.50 0.24 3.28
Sea Trout 2.09 0.57 0.25 2.91
Sea Trout 3.19 0.70 0.42 4.31
Sea Trout 3.65 1.04 4.68
Shrimp 4.61 2.84 0.66 8.11
Shrimp 4.42 2.70 0.67 7.79
Shrimp 2.73 1.57 0.55 4.85
Shrimp 4.73 2.74 0.51 7.98
Shrimp 4.06 3.43 1.21 8.69
Shrimp 5.82 1.82 7.63
Spot 3.63 1.24 0.39 5.26
Spot 4.08 1.39 0.29 5.76
Spot 3.72 1.15 0.35 5.22
Spot 3.23 1.02 4.25
Spot 3.51 0.76 0.36 4.63
Spot 2.64 0.52 3.15
Spot 2.79 0.45 0.21 3.46
Spot 3.20 0.65 3.85
Spot 2.05 2.05
Yellowtail 3.20 1.01 4.21
Yellowtail 3.12 0.91 0.35 4.38
Yellowtail 2.98 1.12 0.44 4.53
Flounder 3.54 0.71 4.26
Whiting 3.45 3.45
Minimum 6.09 3.43 1.21 8.69
Maximum 0.28 0.41 0.21 0.00
Median 3.22 1.18 0.52 4.39
Average 3.32 1.33 0.54 4.47
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ers present in technical toxaphene (>600) that changes in
the composition of the material occurs once released in
the environment. A multitude of studies indicate that tox-
aphene in the environment weathers and the resulting mix-
ture consists of a much smaller number of congeners than
in the original TT. As discussed, the persistent congeners
that make up the human body burden are p-26, p-50,
and p-62. However, a larger number of congeners occur
in fish and other biota. The persistence of the various cong-
eners is determined by their thermodynamic stabilities and
molecular structural energies (Heimstad et al., 2001).
Microbial degradation of toxaphene shows specificity for
the removal of chlorines in particular positions on the mol-
ecule (Ruppe et al., 2003, 2004). In addition, biotic and abi-
otic transformation of toxaphene results in different
mixtures of congeners (Angerhofer et al., 1999).
Table 6 shows the percentage of the three congeners in
biota from a variety of sources (Chan et al., 1998; Chan
and Yeboah, 2000; Skopp et al., 2002a). The percentage
of p-26 ranges from 0.33 to 30%, p-50 ranges from 0.45
to 25%, and p-62 ranges from 0.33 to 13%. The average
percentage of
P
3PC in the mixture is 22%. Table 7 shows
the percentages of the three congeners from fish samples
obtained at a Superfund site collected in 1997 (Maruya,
2000). The percentage of p-26 ranges from 0.28 to 6%, p-
50 ranges from 0.41 to 3.4%, and p-62 ranges from 0.21
to 1.21%. The average percentage of
P
3PC in the mixture
is 4.5%. The samples shown in Table 6 were obtained from
fish obtained at northern latitudes that are generally higher
in fat than fish obtained from more temperate climates,
such as the samples in Table 7. This effect of latitude was
also observed by McHugh et al. (2004). Their higher fat
content and larger size may be reasons for the higher per-
centages of
P
3PC in the coldwater fish.
4.2. Comparison of toxaphene toxicity criteria
One can compare the toxicity criteria for
P
3PC with
that for TT in terms of fish concentrations. For the TT
slope factor, the typical Lifetime Receptor for carcinogenic
effects was defined as an individual exposed from age 0 to
30, 6 years as a child and 24 years as an adult. Age-specific
body weights and fish consumption rates were obtained
from USEPA (1997a). For each year from 1 to 30, the fish
consumption rate in g/day was divided by the body weight.
These resulting values were averaged over all 30 years to
obtain the Lifetime Receptor fish consumption rate
(FCR) or 0.194 g/kg-day (Table 8).
The fish concentration representative of a 1E06 cancer
risk using the TT slope factor in a Lifetime Receptor is
0.011 mg/kg. This calculation was performed iteratively
by substituting a range of fish concentrations in Eq. (2)
shown below until the risk was equal to 1E06
Risk ¼ CSF 
Cfish  IRfish  0:001 kgg  30 yr  365 daysyr
25550
days
lifetime
ð2Þ
where CSF is the cancer slope factor = 1.1 per mg/kg-day,
Risk is the 1E06, Cfish is the concentration in fish (solved
iteratively), IRfish is the lifetime fish ingestion
rate = 0.194 g/kg-day (Table 8).
The application of the tolerable daily intake (TDI) tox-
icity criterion developed in (MATT, 2000) or 0.0069 mg/
kg-day was performed with Eq. (3). The resulting fish con-
centration developed corresponding to an HQ of 1 was
35 mg/kg.
Acceptable ConcCLE in fish ¼ TDICLE
IRfish  0:001 kg=g ; ð3Þ
where TDICLE is the tolerable daily intake for
CLE = 0.0069 mg/kg-day, IRfish is the fish ingestion
rate = 0.194 g/kg-day (Lifetime).
The fish concentration of WT representative of
P
3PC
at 22% of the mixture (Table 6) and at an HQ of 1 for a
Lifetime Receptor is 0.45 mg/kg. The fish concentration
of WT representative of the
P
3PC at 4.5% (Table 7) and
at an HQ of 1 for a Lifetime Receptor is 2.2 mg/kg. Eqs.
(4a) and (4b) shows this calculation.
Table 8
Calculation of fish ingestion rate for lifetime receptor
Age Consumption
(g/day)
Body
weight
(kg)
Yearly average
fish ingestion rate
(g/kg-day)
0 0 9.4 0
1 5.63 11.8 0.477
2 5.63 12.9 0.436
3 5.63 15.1 0.373
4 5.63 17.1 0.329
5 5.63 19.4 0.290
6 7.94 21.7 0.366
7 7.94 25.5 0.311
8 7.94 28.1 0.283
9 7.94 32.7 0.243
10 7.94 35.6 0.223
11 7.27 41.5 0.175
12 7.27 46.9 0.155
13 7.27 55.1 0.132
14 7.27 61.1 0.119
15 7.27 62.8 0.116
16 7.27 65.8 0.110
17 7.27 67.5 0.108
18 7.27 70 0.104
19 7.27 70 0.104
20 7.27 70 0.104
21 10.2 70 0.146
22 10.2 70 0.146
23 10.2 70 0.146
24 10.2 70 0.146
25 10.2 70 0.146
26 10.2 70 0.146
27 10.2 70 0.146
28 10.2 70 0.146
29 10.2 70 0.146
30 10.2 70 0.146
Average for years 0–30 0.194
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Acceptable ConcP 3PC in fish
¼
RfDP 3PC
IRfish  0:001 kg=g %
P
3PC
; ð4aÞ
where RfDP3PC is the reference dose forP
3PC = 2E05 mg/kg-day, IRfish is the fish ingestion
rate = 0.194 g/kg-day (Lifetime), and %
P
3PC is the per-
centage of
P
3PC in the WT mixture.
Substituting values, one obtains
Acceptable Concfish ¼ 2E–05 mg=kg-day
0:194 g=kg-day  0:001 kg=g  22%
¼ 0:45 mg=kg ð4bÞ
4.3. Toxaphene and human cancers
Toxaphene has been shown to disrupt GJIC in nor-
mal human breast epithelial cells and human cancer
cells (Kang et al., 1996; Kao et al., 1995). Because of
the high fat content of artic marine mammals, these ani-
mals represent a reservoir of WT (e.g., Chan and
Yeboah, 2000). The Circumpolar Inuit people consume
large quantities of marine mammals and are highly
exposed to toxaphene relative to the US population
with plasma concentrations of WT up to 4 lg/L (Bjer-
regaard et al., 2001; Sandanger et al., 2003; Walker
et al., 2003; Van Oostdam et al., 2005). The Inuit have
approximately twentyfold lower breast cancer rates than
comparison populations so clearly this concentration is
less than a frank effect level.
This additional information indicates that the toxicity
assessment presented here is very likely to be protective
of tumor promotion in humans and other endpoints as
well. Current human exposure to toxaphene is to WT,
not TT and the continued use of the more stringent toxicity
assessment for technical toxaphene will result in inaccurate
risk/hazard estimates and possibly unnecessary and overly
costly cleanups.
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